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Abstract Clostridium difficile infection (CDI) is increasingly
found in children worldwide, but limited data are available
from children living in southern Europe. A 6-year retrospec-
tive study was performed to investigate the epidemiology,
clinical features, treatment, and risk of recurrence in Italy.
Data of children with community- and hospital-acquired
CDI (CA-CDI and HA-CDI, respectively) seen at seven pedi-
atric referral centers in Italy were recorded retrospectively.
Annual infection rates/10,000 hospital admissions were cal-
culated. Logistic regression was used to investigate risk fac-
tors for recurrence. A total of 177 CDI episodes was reported
in 148 children (83 males, median age 55.3 months), with a
cumulative infection rate of 2.25/10,000 admissions, with no
significant variability over time. The majority of children
(60.8 %) had CA-CDI. Children with HA-CDI (39.2 %) had
a longer duration of symptoms and hospitalization (p = 0.003)
and a more common previous use of antibiotics (p = 0.0001).
Metronidazole was used in 70.7 % of cases (87/123) and
vancomycin in 29.3 % (36/123), with similar success rates.
Recurrence occurred in 16 children (10.8 %), and 3 (2 %) of
them presented a further treatment failure. The use of metro-
nidazole was associated with a 5-fold increase in the risk of
recurrence [odds ratio (OR) 5.18, 95 % confidence interval
(CI) 1.1–23.8, p = 0.03]. Short bowel syndrome was the only
underlying condition associated with treatment failure (OR
5.29, 95% CI 1.17–23.8, p = 0.03). The incidence of pediatric
CDI in Italy is low and substantially stable. In this setting,
there is a limited risk of recurrence, which mainly concerns
children treated with oral metronidazole and those with short
bowel syndrome.
Abbreviations
CD Clostridium difficile
CDI Clostridium difficile infection
HA-CDI Hospital-acquired CDI
CA-CDI Community-acquired CDI
PCR Polymerase chain reaction
EIA Enzyme immunoassay
GDH Glutamase dehydrogenase
SITIP Italian Society of Pediatric Infectious Diseases
Introduction
A dramatic increase in the incidence of Clostridium
difficile infection (CDI) has been reported in the past de-
cade worldwide. This change in epidemiology is probably
linked to an excess of antibiotics and other causes of mi-
croflora disruption, to the concomitant emergence of hy-
pervirulent epidemic strains (e.g., NAP1/BI/027), and to
the increase of potentially highly susceptible individuals
[1–3]. The role of C. difficile (CD) in infancy and
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childhood is still a matter of debate. This sporogenic an-
aerobic organism is responsible for a broad spectrum of
diseases in children, ranging from a self-limiting secretory
diar rhea to l i fe - threa tening condi t ions , such as
pseudomembranous colitis, toxic megacolon, intestinal
perforation, and septic shock [3]. On the other hand,
asymptomatic CD colonization is common in infants and
young children (2–75 %), and seems to be related to factors
such as age, type of delivery, and feeding [4]. However, the
recent change in epidemiology has been confirmed also for
the pediatric population, and some evidence reports a sig-
nificant increase of both hospital- and community-acquired
CDI (HA-CDI and CA-CDI, respectively) incidence in
children living in western countries [5, 6], with rates that
vary between 12.8 and 40/10,000 hospital admissions, ac-
cording to different populations [7, 8].
Recurrence is a relatively common complication of CDI
and about 20–30 % of children with CDI experience a new
episode of infection after first-line treatment [5, 9, 10]. Risk
factors for recurrent CDI in children have been recently re-
ported and include previous use of antibiotics, malignancy,
recent surgery, and presence of respiratory devices [9–11].
The epidemiology and risk factors of CDI in children living
in southern Europe and Mediterranean countries are poorly
known. Available evidence is limited to small populations
(less than 30 cases) or sporadic case reports [12–14].
The Italian Society of Pediatric Infectious Diseases (SITIP)
promoted a retrospective study to investigate the epidemiolo-
gy of CDI in Italian children and analyze clinical features,
therapeutic options, outcomes, and risk factors for recurrence.
Materials and methods
We conducted a 6-year retrospective, multicenter, observa-
tional study including all children (birth to 18 years of age)
with confirmed CDI admitted between January 2008 and
December 2013 in seven large pediatric centers in Italy. The
enrolling centers provide tertiary care to Italian children. Most
children seen in these institutions belong to at-risk populations
with chronic diseases.
Definitions
CDI was defined by the presence of diarrhea, defined as ≥3
watery or loose stools in the previous 24 h [15], associated
with a positive finding of toxigenic CD in the stools (toxins A
and/or B or binary toxin) or the presence of pseudo-
membranous colitis on endoscopy or histology, according to
recent guidelines [16, 17]. The modality of CD detection
slightly varied according to institution and year of enrollment.
Three institutions used enzyme immunoassay (EIA) for the
whole study period. Real-time polymerase chain reaction
(rPCR) for CD toxins was used in one institution for the whole
study period. Another institution used EIA from 2008 to 2010
and then introduced rPCR for CD toxins. Two institutions
used a two-step diagnostic approach with glutamase dehydro-
genase (GDH) test as the first step, and successive confirma-
tion of the strain toxigenicity rPCR for the toxins. CD culture
was not performed routinely.
The presence of fever and vomiting, and the main charac-
teristics of stools (including mucus and/or blood) were record-
ed, together with other clinical data. CD-positive children
were included in the study only if other routine microbiolog-
ical investigations for common intestinal pathogens were neg-
ative (i.e., rotavirus and standard stool culture for Salmonella,
Shigella, or Campylobacter).
According to guidelines, recurrent CDI was defined if di-
agnostic criteria of CDI were met within 8 weeks of initial
diagnosis after documented symptom resolution [16, 18, 19].
Infection was defined as hospital-acquired (HA-CDI) if onset
of symptoms occurred >48 h after admission, or less than
4 weeks after discharge from a healthcare facility. Infection
was defined as community-acquired (CA-CDI) if onset of
symptoms occurred in the community or within 48 h of ad-
mission to a hospital, or if symptom onset was >12weeks after
the last discharge from a hospital. Infection was defined as
indeterminate if symptom onset occurred between 4 and
12 weeks from a hospital discharge; however, indeterminate
CDI in our population (n = 1) was classified as community-
acquired for study purposes [17].
Data collection
The pediatricians managing single patients, in collaboration
with the microbiology units of each center, collected the fol-
lowing data retrospectively by using standardized forms: pa-
tient’s age, gender, underlying conditions, or prematurity; date
and ward at hospital admission, CDI-related signs and symp-
toms, recent healthcare-associated exposures including ad-
ministration of antibiotics in the past 2 months, use of immu-
nosuppressive therapy, CDI treatment including antibiotics
(drug, formulation, and dose), probiotics (strain) and other
treatments, patient outcomes (including treatment failure, re-
currence, and death), duration of symptoms, and length of
hospital stay and treatment. All clinical and demographic data
were extracted manually from medical records and the forms
were sent to the coordinator center and inserted into a
Microsoft Office Excel workbook.
In order to calculate the annual infection rate, each center
reported to the coordinator the total number of hospital admis-
sions for each year of observation.
The study was approved by the Council of the SITIP (ses-
sion of May 2014) and has been conducted according to the
principles expressed in the Declaration of Helsinki. All pa-
tients’ data were analyzed and reported anonymously.
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Statistical analysis
Infection rates were reported as the number of CDIs recorded
in single centers normalized for 10,000 hospital admissions
for each year of observation. The number of admissions was
limited to pediatric patients for those centers that also mange
adults. Cumulative infection rates with relative 95 % confi-
dence intervals (CIs) for annual infection rates were used to
compare infection rates according to the year of observation
and to the diagnostic method for CD detection.
Continuous variables were summarized and reported as
means and standard deviation (SD). Categorical variables
were summarized and reported as frequencies and percent-
ages. Clinical characteristics and underlying conditions of
children with HA-CDI and CA-CDI were compared by using
the t-test and non-parametric the Mann–Whitney test. The age
of children was reported in months and interquartile range
(IQR). Categorical variables were compared by means of
Fisher’s exact test or the Chi-square test, as appropriate.
Univariate analysis of variables influencing the risk of recur-
rence was performed using the logistic regression analysis and
Cox’s regression model. Risk was reported as odds ratio (OR)
with 95 % CI. Multivariate analysis considered all therapeutic
options included in the univariate analysis and the setting of
CDI. Two-sided p-values ≤0.05 were considered statistically
significant. Statistical analysis was performed using the SPSS
Statistics software (version 20.0 for Windows; SPSS Inc.,
Chicago, IL, USA).
Results
CDI rates and clinical features
In the 6-year study period, 167 CDI episodes were recorded in
148 children (83 males, median age 55.3 months), with a
cumulative infection rate of 2.25/10,000 hospitalized children.
The general characteristics, clinical features, and underlying
clinical conditions of enrolled children are reported in Table 1.
The infection rate varied from a maximum of 5.1 in 2009 to a
minimum of 1.15/10,000 in 2010 (Fig. 1). The infection rates
with 95 % CI did not change during the study period
(p > 0.05). No significant difference was observed among dif-
ferent institutions, although a slight (but not significant) trend
toward increase was observed in centers located in northern
Italy when compared to those in the southern part of the coun-
try. This result was confirmed also when the infection rates
were analyzed according to the diagnostic methods used for
CD detection in different enrolling centers (Table 2). Although
the centers using molecular diagnostic tests (mainly the two-
step diagnostic approachwith GDH and rPCR) showed slight-
ly higher rates than the others, no significant difference in
infections rates (with 95 % CI) was observed in the 6 years
of observation (Table 2).
The majority of infections (60.8 %) met the definition of
CA-CDI (Table 1). Children who experienced HA-CDI (58,
39.2 %) had a longer hospitalization (p = 0.003) and a slightly
longer duration of symptoms (Table 1).
The majority of children (82.5 %) had underlying condi-
tions that can increase the risk of CDI; however, this pattern
was more frequent in HA-CDI than in CA-CDI (Table 1).
Previous use of antibiotics was reported in 79 patients
(53.4 %), being significantly more common in children with
HA-CDI (p = 0.0001) (Table 1).
Chronic bowel diseases (50, 33.7 %) and hemato-
oncologic diseases (27, 18.2 %) were the most commonly
reported underlying chronic conditions. Chronic renal dis-
eases and history of prematurity were significantly more com-
mon in children presenting with HA-CDI. Inflammatory bow-
el diseases were more common in children with CA-CDI
(Table 1).
A child with leukemia and HA-CDI died after the first
treatment with vancomycin and probiotics, resulting in a mor-
tality rate of 0.67 %.
CDI treatment
Of the 148 patients, 123 underwent specific antibiotic treat-
ment (83.1 %); in the remaining patients, symptoms resolved
rapidly and without treatment. The first-line treatment was
metronidazole in 70.7% of children (87/123) and vancomycin
in 29.3 % (36/123). Among children with HA-CDI, metroni-
dazole was prescribed in 63.8 % of cases and vancomycin in
24.1 %. A similar proportion was observed in CA-CDI,
55.6 % and 24.4 %, respectively. Although the rate of not
treated children was slightly higher in CA-CDI (20 %) than
HA-CDI (12 %), this difference was not statistically signifi-
cant (p = 0.39). Among the 25 patients (16.9 %) who did not
receive specific antibiotic treatment for CD, 15 (60 %) had a
recent exposure to antibiotics (mainly penicillins, cephalospo-
rins, and fluoroquinolones), three had inflammatory bowel
diseases, one had a history of minimal bowel resection, and
the remaining six had no underlying conditions. Most of these
patients received diagnosis by using rPCR.
Probiotics were used in 35 episodes of CDI. In most cases
(28/35, 80 %) they were used in association with antibiotics
for the treatment of HA-CDI (15, 53.5 %) or CA-CDI (13,
46.4 %). However, in 7 episodes (20 %), probiotics were used
as the only treatment. Nine different formulations were used
(single strains or mix of probiotics); Lactobacillus reuteriwas
the most common single strain reported (10/35, 28.5 %).
No difference in treatment success rate was observed com-
paring children receiving probiotics or not, and the same re-
sults were observed if outcomes were analyzed according to
different probiotic strains.
Eur J Clin Microbiol Infect Dis (2017) 36:177–185 179
Fig. 1 Clostridium difficile
infection (CDI) rates among
children living in Italy. The bars
report the rates for each year of
observation from 2008 to 2013
normalized for 10,000 hospital
admissions. The dotted line
indicates the cumulative rate,
calculated by dividing the total
number of episodes of CDI by the
total number of hospital
admissions normalized for 10,000
admissions. The p-values express
the significance of variation
among all different annual rates;
values <0.05 are considered to
express significant variation. NS:
not significant
Table 1 Clinical features of 148
Italian children with community-
acquired and hospital-acquired
Clostridium difficile infections*
Parameters All CDI CA-CDI HA-CDI p-Value
No. of children (%) 148 90 (60.8) 58 (39.2)
Male (%) 83 (56.1) 52 (57.7) 31 (53.4) 0.60
Median age (months, IQR) 55.3 (87.7) 47.3 (79.2) 59.7 (90.8) 0.28
Symptoms
Duration of symptoms (mean days ± SD) 18.56 (27) 15.3 (23.1) 23.4 (31.7) 0.07
Duration of hospitalization (mean days ± SD) 25.1 (46.3) 13.9 (27.2) 42.5 (62.2) 0.003
Fever > 8 °C 62 (41.8) 34 (37.7) 28 (48.2) 0.23
Bloody stools 40 (27.0) 24 (26.6) 16 (27.5) 1.00
Vomiting 38 (25.6) 25 (27.7) 13 (22.4) 0.56
Mucus in stools 27 (18.2) 19 (21.1) 8 (13.7) 0.28
Moderate-to-severe dehydration 23 (15.5) 14 (15.5) 9 (15.5) 1.00
Abdominal pain 12 (8.1) 9 (10) 3 (5.1) 0.36
Ileus 4 (2.7) 1 (1.1) 3 (5.1) 0.30
Underlying conditions
Previous use of any antibiotics (%) 79 (53.4) 38 (42.0) 42 (72.4) 0.0001
Previous use of ≥2 antibiotics (%) 37 (25) 13 (14.4) 24 (41.4) 0.0001
Inflammatory bowel diseases (%) 23 (15.5) 19 (21.1) 4 (6.8) 0.021
Non-inflammatory intestinal diseases (%) 14 (9.5) 9 (10) 5 (8.6) 0.95
Short bowel (%) 13 (8.7) 8 (8.8) 5 (8.6) 0.99
Oncologic diseases (%) 19 (12.8) 10 (11.1) 9 (15.5) 0.46
Chronic neurologic diseases (%) 11 (7.4) 4 (4.4) 7 (12) 0.11
Chronic renal diseases (%) 8 (5.4) 1 (1.1) 7 (12) 0.006
Bone marrow transplantation (%) 6 (4.0) 2 (2.2) 4 (6.8) 0.21
History of prematurity (%) 4 (2.7) 0 (0) 4 (6.8) 0.022
Solid organ transplantation (%) 2 (1.3) 1 (1.1) 1 (1.7) 0.99
Immunodeficiency and HIV infection (%) 1 (0.6) 1 (1.1) 0 (0) 1.00
No at-risk conditions (%) 26 (17.5) 22 (24.4) 4 (6.8) 0.007
CDI: Clostridium difficile infection; CA-CDI: community-acquired CDI; HA-CDI: hospital acquired-CDI; HIV:
human immunodeficiency virus
*Data reported in the table refer to the first episode of infection
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CDI recurrence
First-line treatment was successful in 89.2 % of children (133/
148). Sixteen children (10.8 %) experienced a recurrence and
3 (2 %) of them presented a further failure after the second
treatment. Recurrences were treated with metronidazole in 10
cases (62.5 %) (oral in seven cases and intravenous in three)
and vancomycin in 6 cases (37.5 %). The two antibiotics had
similar success rates in resolving CDI symptoms (80 % and
83.3 %, respectively, p = 1.00).
Table 3 reports the analysis of potential risk factors for CDI
recurrence. Children with short bowel syndrome had a higher
risk of developing CDI recurrence (OR 5.29, 95 % CI 1.17–
23.8, p = 0.03). The risk of recurrence was similar between
children with HA-CDI and CA-CDI. None of the other well-
known risk factors were associated to higher risk of
recurrence.
The use of metronidazole was associated with a 5-fold
increase in recurrence, and this risk was detected in both the
univariate and the multivariate analyses (Table 4). When dif-
ferentiated according to the route of administration, this risk
was confirmed for oral metronidazole (OR 3.24, 95 % CI
1.00–10.7, p < 0.05), but not for the intravenous route (OR
1.42, 95% CI 0.28–6.91, p = 0.66). The dose of metronidazole
used ranged between 15 and 40 mg/kg/day; however, doses
<30 mg/kg/day were not significantly related to the risk of
recurrence (p = 0.26). The association of probiotics with met-
ronidazole reduces the risk of first-line treatment failure
(Table 4). In addition, three recurrences were treated with this
association and none of them experienced further episodes.
Discussion
The scientific and medical interest about CDI increased
worldwide in the last decade following the evidence of signif-
icant changes in epidemiology and increasing morbidity re-
ported in the adult population. Although the problem among
children seems smaller, the pediatric world is moving in the
same direction, and an increase in CDI incidence has been
reported in North America [5, 7, 8] and northern Europe [20].
We found a CDI rate that was substantially stable in the 6-
year period of observation, with an infection rate that varies
from 3.75 in 2008 to 2.02/10,000 hospital admissions in 2013.
These findings contrast with a previous Italian experience
that reported a trend toward increase in the last several years
[14]. However, in that study, the authors reported results from
a smaller population, seen at a single center and diagnosed by
using a two-step diagnostic protocol, based on the GDH test
and rPCR for toxins. In our experience, the centers using this
two-step diagnostic approach showed higher infection rates
Table 2 Infection rates according to diagnostic method for the detection of Clostridium difficile
Diagnostic method Clostridium difficile infection rate (95 % CI)
Year of observation p-Value
2008 2009 2010 2011 2012 2013
EIA 5.85 (2.62–13.0) 1.94 (0.73–5.17) 6.38* (2.65–15.3) 1.26 (0.17–8.94) 1.22 (0.17–8.66) 2.45 (0.61–9.79) NS
GDH/PCR 2.63 (1.09–6.31) 6.41 (3.55–11.6) 3.55* (1.59–7.90) 7.29* (4.03–13.1) 2.84 (1.06–7.56) 5.32 (2.53–11.1) NS
PCR – – 0.45 (0.18–1.2) 2.6 (1.8–3.74) 1.78 (1.14–2.75) 1.58 (0.98–2.54) NS
EIA: enzyme immunoassay for Clostridium difficile toxins A and/or B; PCR: polymerase chain reaction for Clostridium difficile toxins A and/or B;
GDH/PCR: two-step methodology: glutamase dehydrogenase (GDH) test as the first step, and successive confirmation of the strain toxigenicity Real-
time polymerase chain reaction (rPCR) for the toxins; NS: Not significant
p-Values express the difference among the CDI rates and is calculated comparing the 95 % CI of single annual rates; values <0.05 are considered
significant
*p < 0.05 if compared to PCR
Table 3 Risk factors for Clostridium difficile infection recurrence in
148 Italian children
Risk factors OR 95 % CI p-Value
Hospital- vs. community-acquired CDI 1.89 0.65–5.5 0.24
Any underlying chronic disease 3.24 0.40–25.8 0.26
Inflammatory bowel diseases 0.96 0.19–4.7 0.96
Other chronic bowel diseases 2.75 0.65–11.53 0.16
Short bowel syndrome 5.29 1.17–23.8 0.03
Chronic neurologic diseases 0.87 0.10–7.38 0.90
Chronic renal diseases 0.94 NA 0.33
History of prematurity 3.09 0.30–31.7 0.34
Hemato-oncologic diseases 1.82 0.46–7.1 0.38
Bone marrow transplantation 1.82 0.19–16.7 0.59
Solid organ transplantation 0.2 NA 0.63
Use of immunosuppressive drugs 1.2 NA 0.27
HIV infection 0.1 NA 0.73
Co-infection with enteric pathogens 0.99 0.98–1.00 0.47
OR: odds ratio; CI: confidence interval; NA: not assessable
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(mean rate 4.67/10,000) than those recorded in centers using
EIA or rPCR alone (3.18/10,000, p > 0.05).
In addition, it should be noted that CDI rates recorded in
Italy are 5- to 10-fold lower than those reported in children
living in the United States, where the rates vary between 12.8
and 40/10,000 admissions [7, 8]. This difference is relevant
even if the incidence is calculated only in Italian centers using
molecular diagnosis (below 5/10,000, Table 2).
These findings demonstrated that the epidemiology of pe-
diatric CDI in a southern European country, such as Italy,
might be significantly different from northern Europe and
America. The reasons for this difference are unclear and need
to be specifically investigated; however, factors such as life-
style or diet, which dramatically affect the composition of
intestinal microbiota, may play a relevant role. A further hy-
pothesis that may explain a variation in epidemiology is the
potential exposition to contaminated foods, whose distribution
may vary from country to country. Toxigenic CD strains have
been found in ready-to-eat salad, meat, shellfish, dairy prod-
ucts, and wastewater [21–24], and the use of these products
may account for part of community-acquired CDI. The latter
is responsible for the majority of cases in pediatric reports [5,
25], as well as in our population.
On the other hand, the evidence of a low CD prevalence in
Italy is also surprising, considering that CDI is strongly related
to the use and abuse of antibiotics [26, 27], and that the con-
sumption of antibiotics in children living in Italy is significant-
ly higher than that reported in other European countries
[28–30]. In contrast, the use of antibiotics is strictly under
control in poultry and foodstuffs.
Current antibiotic treatments for CDI are able to resolve
90 % of acute CDI; however, treatment failure is certainly
the major problem in the management of patients with CDI
in either adulthood or childhood. In addition, relapses/
recurrences are associated with increased severity and poor
outcomes. Several new therapeutic approaches have been pro-
posed in the last several years to reduce the rate of recurrence.
Although selected treatment options such as fidaxomicin [31],
fecal microbiota transplantation [32–34], or CD toxin-targeted
monoclonal antibodies [35, 36] are gaining importance and
consensus in adult medicine, most of them have not been
tested in large pediatric populations [37].
In our study, 10 % of children experienced a recurrence
after first-line treatment. This rate is significantly lower than
that reported in North America, where 18–31 % of children
present a recurrence [5, 38].
We found that children receiving metronidazole alone as
first-line treatment had a 5-fold higher risk of developing re-
currence compared to children receiving vancomycin or a
combination of antibiotics and probiotics. The risk seems to
be related to oral administration rather than the intravenous
route; however, this difference should be considered with cau-
tion, since only a small proportion (about 5 %) of children
received intravenous doses. Metronidazole is almost
completely absorbed in the small intestine; however, its con-
centration in the colon varies according to stool pattern and
intestinal motility [39]. In any case, several factors might in-
fluence the efficacy of oral administration in children, includ-
ing the difficulty of administration in younger children due to
the lack of pediatric formulation, the drug dilution entrusted to
families, the co-administration of other drugs, and the variabil-
ity in drug doses. In our population, oral metronidazole was
administered in variable doses ranging from 15 to 40 mg/kg/
day; however, the change in dose was not related to the risk of
CDI recurrence.
Although we found wide 95 % CIs, this finding was con-
firmed in both univariate and multivariate analyses. The width
of intervals reported may be related to the relatively small size
Table 4 Impact of treatment on
the risk of Clostridium difficile
infection recurrence
Treatment Univariate analysis Multivariate analysis
Any recurrence OR 95 % CI p-Value OR 95 % CI p-Value
Metronidazole alone 5.18 1.1–23.8 0.03 6.38 1.01–40.1 0.04
Vancomycin alone 0.44 0.09–2.0 0.30 1.42 0.21–9.4 0.71
Probiotics alone 1.28 0.14–11.2 0.82 1.68 0.47–5.9 0.41
Metronidazole + probiotics* 2.52 0.62–10.1 0.19 – – –
Vancomycin + probiotics* 0.82 NA 0.36 – – –
Two or more recurrences OR 95 % CI p-Value OR 95 % CI p-Value
Metronidazole alone 0.69 0.95–5.06 0.71 1.8 0.13–24.1 0.65
Vancomycin alone 3.21 0.43–23.8 0.24 4.8 0.36–65.3 0.23
Metronidazole + probiotics 4.11 0.35–30.7 0.16 4.39 0.58–35.3 0.51
OR: odds ratio; CI: confidence interval; NA: not assessable
*Single daily dose of different probiotic strains added to antibiotic treatment, including: Lactobacillus reuteri (n =
10), Lactobacillus rhamnosus GG (n = 2), Lactobacillus casei DG (n = 1), Lactobacillus rhamnosus (n = 1)
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of the population and to the difference in the number of pa-
tients receiving metronidazole and vancomycin as first-line
treatment.
Evidence in adults demonstrated no difference in recur-
rence between metronidazole and vancomycin for both mild
and severe CDI, neither in monotherapy nor in combination
[40, 41]. However, although evidence from pediatric age pa-
tients is more limited, Khanna et al. reported an 18 % recur-
rence rate in children receiving metronidazole as first-line
treatment and no recurrence in those receiving vancomycin
[5], in keeping with our results.
The CD resistance to metronidazole might partially justify
the relapse after first-line treatment; however, this is a rare
event reported in 1–6.5 % of pediatric cases [42]. In our ex-
perience, CD culture was not routinely performed for the di-
agnosis of CDI. For that reason, and for the retrospective
nature of the study, data on CD antibiotic resistance profile
was available only for a minority of patients enrolled in a
single center. In the 18 specimens available for culture
(12 % of total events), no in vitro resistance to metronidazole
was observed.
Position papers released by relevant societies currently rec-
ommend metronidazole as first-line treatment for the initial
episode of CDI in children [43, 44]. This recommendation is
based on weak evidence, but is essentially aimed to minimize
the overuse of vancomycin and reduce the potential risk of
emergence of antibiotic resistance. Any potential difference in
the risk of CDI recurrence between metronidazole and vanco-
mycin needs to be specifically investigated in prospective
studies on pediatric population. However, whether our find-
ings would be confirmed by further data, the role of oral met-
ronidazole as first-line treatment would need to be reviewed.
Some underlying conditions have been recently identified
as risk factors for recurrent CDI in children, including previ-
ous use of antibiotics, malignancy, recent surgery, and trache-
otomy [9–11]. In our population, short bowel syndrome was
the only underlying condition that significantly predisposed to
CDI recurrence. Patients with this condition underwent major
intestinal surgery, received parenteral nutrition, and, not rare-
ly, undergo heavy antibiotic therapy for central-line infections,
intestinal bacterial overgrowth, and other infections. All these
factors might play a role in the proliferation of CD, disruption
of intestinal microflora, and the potential development of CDI
recurrences.
The retrospective nature represents a limitation of our
study. In order to study the epidemiology of an emerging
infection like CDI, prospective data on large populations are
needed. However, this retrospective study collected data from
several representative pediatric tertiary care centers in Italy,
covering a quite extended period and provided information
on the largest pediatric population currently published in
European countries. A further limitation of our study is the
variability in CD detection methodology that was recorded in
the enrolling institutions during the study period. New, more
sensitive diagnostic approaches, including toxin-targeted
rPCR or a two-step approach with GDH and rPCR have been
proposed and largely introduced in many institutions. These
diagnostic assays are changing the capability of detecting CD
in stools [45], but also have a relevant impact on the epidemi-
ology of CDI [46]. In our observational study, these methods
were used during the study period by three institutions and one
institution introduced rPCR in 2010. However, to minimize
this bias, infection rates were analyzed in accordance with the
diagnostic assay and no significant difference in incidence
was observed during the study period.
In conclusion, we demonstrated that CDI has a low and
stable incidence and a limited morbidity in children in Italy.
The infection rate and risk of recurrence are significantly low-
er than those reported in other western countries. In this con-
text, children receiving oral metronidazole as first-line treat-
ment and those with short bowel syndrome are at risk of de-
veloping CDI recurrence.
Further studies on large pediatric populations are needed to
monitor infection in other European countries and investigate
potential factors that can impact on the risk of CDI in this
population.
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